

- This study provides the first head-to-head comparison of the viral kinetics profiles of telbivudine and tenofovir for treatment-naïve patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
- This randomized, open-label study compared 46 HBeAg-positive patients during 12-week treatment with telbivudine ($n = 16$), tenofovir ($n = 14$), or the combination of telbivudine plus tenofovir ($n = 16$).
- Result shows that viral kinetics parameters were comparable between the telbivudine and tenofovir groups with respect to viral clearance per day, rate of infected cell loss per day and efficiency of blocking viral replication.
- Efficiency in blocking viral production was slightly improved in the combination treatment group compared to the monotherapy groups.

This summary slide represents the opinions of the authors. This study and the article processing charges were funded by Novartis Pharma AG, Basel, Switzerland. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).